Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance

Abstract

Whether intensive gylcaemic control can reduce the cardiovascular complications in type 2 diabetes has been answered in three clinical trials (ACCORD, ADVANCE and VADT). All three studies measured microvascular complications as well as macrovascular end points. It is important to initiate intensive glycaemic control early in the course of diabetes. Type 2 diabetes mellitus patients require lifestyle modification plus combinations of insulin sensitisers and insulin secretagogues. It target glycaemic control is not achieved then either incretin minetics or insulin can be added.